Results 51 to 60 of about 11,074 (164)

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

Alectinib Superior to Crizotinib for ALK+ NSCLC

, 2017
Findings from the global phase III ALEX trial unequivocally show that alectinib is superior to crizotinib as first-line therapy for ALK+ non-small cell lung cancer.

core   +1 more source

Low‐Concentration Enhancement Effect: Enabling Sensitive Detection of EML4‐ALK Variants via Multiplex RT‐MIRA

Journal of Clinical Laboratory Analysis, EarlyView.
This study developed an optimized multiplex RT‐MIRA assay for the simultaneous detection of EML4‐ALK variants, achieving single‐copy sensitivity. Unexpectedly, during the development of the reaction system, we discovered a “low‐concentration enhancement effect,” where reducing primer or probe concentrations within a specific range markedly improved ...
Xiao‐Dong Ren, Xi‐Yao Luo, Jin‐Mi Li, Xian‐Ge Sun, Jing Lv, Hua‐Liang Xiao, Qiu‐Shi Wang, Hong Wang, Chun‐Yan Wang, Hao‐Zheng Li, Qing Huang   +10 more
wiley   +1 more source

Real‐World Outcomes of Brigatinib Compared to Alectinib as a Second‐Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non‐Small Cell Lung Cancer Patients

Thoracic Cancer
Background Second‐generation anaplastic lymphoma kinase (ALK) inhibitors, including alectinib and brigatinib, are widely used in patients with ALK‐positive non‐small cell lung cancer (NSCLC) who develop resistance or progress on crizotinib. However, real‐
Min Jee Kim, Hyun Seok Kwak, Eun Nim Koh, Cheol‐Kyu Park, Young‐Chul Kim, In‐Jae Oh, Seung Joon Kim, Jun Hyeok Lim, Jeong‐Seon Ryu, Chang Min Choi   +9 more
doaj   +1 more source

Nail Toxicities Associated With Anticancer Therapies in Children

JEADV Clinical Practice, EarlyView.
ABSTRACT Nail toxicities are a frequent yet often underrecognized component of dermatologic adverse events in children receiving anticancer therapies. Both conventional cytotoxic chemotherapy and newer targeted agents can affect the nail matrix, nail bed and periungual tissues, producing a broad spectrum of clinical manifestations that range from ...
Luca Rapparini, Michela Starace
wiley   +1 more source

Clinical and Imaging Features of Tepotinib‐Induced Interstitial Lung Disease in the Post‐Marketing Setting in Japan

Cancer Science, Volume 117, Issue 10, Page 2827-2837, October 2026.
This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato, Tomohisa Baba, Masahiro Endo, Shehla Endo, Eisuke Horii, Masahiko Kusumoto   +5 more
wiley   +1 more source

Poorly differentiated lung adenocarcinomas with concurrent ALK and CD30 expression: a diagnostic pitfall mimicking ALK‐positive anaplastic large‐cell lymphoma

Histopathology, EarlyView.
Poorly differentiated lung adenocarcinomas with concurrent anaplastic lymphoma kinase (ALK) and CD30 expression closely mimic ALK‐positive anaplastic large‐cell lymphoma, creating a significant diagnostic pitfall. Accurate classification requires comprehensive integration of clinical, radiologic, morphologic, immunophenotypic and molecular findings ...
Jietian Jin, Wenjian Cen, Qin Yan, Yangshan Chen, Chaoyun Huang, Yanfeng Feng, Neng Jiang   +6 more
wiley   +1 more source

Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC [PDF]

, 2022
Alectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene.
Wiraputri, Anindita Kartika, Pitoyo, Ceva Wicaksono, Rumende, Cleopas Martin, Audita, Fatira Ratri   +3 more
core   +1 more source

Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status

Clinical Case Reports, 2017
Key Clinical Message Alectinib shows remarkable efficacy against anaplastic lymphoma kinase (ALK)‐positive nonsmall cell lung cancer (NSCLC), with minimal adverse effects. Therefore, alectinib may provide a survival benefit to ALK‐positive NSCLC patients
Osamu Kanai, Young Hak Kim, Koichi Nakatani, Kohei Fujita, Tadashi Mio   +4 more
doaj   +1 more source

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis

Frontiers in Oncology, 2021
ObjectiveTo systematically evaluate the efficacy and safety of alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer.MethodsStudies about the efficacy of alectinib versus crizotinib in the ...
Hao Tang, Longyu Jin, Zhang Zhang, Zhibin Jiang, Zeeshan Malik   +4 more
doaj   +1 more source